Current Report · Items 2.02, 9.01 · 8-K

BridgeBio Oncology Therapeutics, Inc.

BBOTNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed May 12, 2026Accepted May 12, 2026, 5:07 PM EDTCIK 1869105Accession 0001193125-26-219801

Company context

Helix Acquisition Corp. II (Nasdaq: HLXB) is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Helix Acquisition Corp. II raised $184 million in its initial public offering on February 9, 2024. Helix is sponsored by affiliates of Cormorant Asset Management and is headquartered in Boston, Massachusetts.

Current securities

BBOTNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On May 12, 2026, BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Filed exhibits (1)

EX-99.1 (by filename) bbot-ex99_1.htm

EX-99.1 2 bbot-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress • Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs • Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor • Clinical readouts expected in the second half of 2026 across all three programs • Cash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., May 12, 2026 - BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress. BBOT's portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition of KRAS in both its ON and OFF states, pan-KRAS coverage across major KRAS mutations, and disruption of RAS-driven PI3Kα activation. Together, these assets uniquely position BBOT to achieve safe, concurrent, high-level suppres…

Open exhibit ↗